预约演示
更新于：2025-05-16
Dipyridamole
双嘧达莫
更新于：2025-05-16
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H40N8O4 |
InChIKeyIZEKFCXSFNUWAM-UHFFFAOYSA-N |
CAS号58-32-2 |
关联
68
项与 双嘧达莫 相关的临床试验NCT06824454
Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients
CTR20244819
双嘧达莫片在健康受试者中的单剂量、随机、开放、交叉、两周期、空腹人体生物等效性试验
CTR20242878
双嘧达莫片在健康受试者中的单剂量、随机、开放、交叉、双周期、空腹喝餐后人体生物等效性试验
100 项与 双嘧达莫 相关的临床结果
登录后查看更多信息
100 项与 双嘧达莫 相关的转化医学
登录后查看更多信息
100 项与 双嘧达莫 相关的专利（医药）
登录后查看更多信息
10,972
项与 双嘧达莫 相关的文献（医药）2025-06-01Journal of molecular and cellular cardiology plus
Targeting the CD39/CD73 pathway: New insights into cardiac fibrosis and inflammation in female cardiac surgery patients
Article
作者: Mahmood, Eitezaz ; Khan, Adnan ; Robitaille, Mark ; Bu, Yifan ; Khabbaz, Kamal R ; Robson, Simon C ; Bose, Ruma ; Mahmood, Feroze ; Matyal, Robina ; Poulin, Marie-France
Women undergoing cardiac surgery suffer from worse outcomes than their male counterparts. The reasons for this disparity are multifactorial, but the loss of the protective effects of estrogen likely plays a role. Estrogen acts on the CD39/CD73 purine pathway, and loss of estrogen effects may contribute to the increased inflammation seen in post-menopausal women. We aimed to compare CD39/CD73 expression and downstream fibrosis, and inflammation in men and women undergoing cardiac surgery and then used an ovariectomy/high fat diet mouse model to approximate women who present for cardiac surgery to test therapeutics. We found decreased CD39 and CD73 in women compared to men, which was associated with increased fibrosis. Apyrase supplementation (a CD39 mimetic) improved ejection fraction and decreased E/e'. Increased CD73 function (via dipyridamole) decreased fibrosis. This study demonstrates the importance of purinergic dysfunction in cardiovascular disease in women and presents two potential therapeutics to improve cardiac health via manipulation of purine pathways.
2025-05-04Expert Opinion On Drug Safety
Compartment syndrome associations with drugs: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)
Article
作者: Yang, Xueting ; Shu, Yunfeng ; Tang, Juan ; Kong, Wenqiang ; Wan, Jie
BACKGROUND:
Compartment syndrome is an uncommon but life-threatening condition. No study has comprehensively compared compartment syndrome (CS) association with available drugs. The objective of this study was to estimate the association between CS and drugs using the FDA Adverse Event Report System (FAERS).
RESEARCH DESIGN AND METHODS:
FAERS reports from the first quarter of 2004 to the third quarter of 2023 were analyzed. The Medical Dictionary for Regulatory Activities (MedDRA) was used to identify CS cases. Reporting odds ratio (ROR), corresponding to 95% confidence intervals (95% CI) were calculated to detect a positive signal.
RESULTS:
A total of 2197 reports were considered in the study after the inclusion criteria were applied. Totally 100 drugs were found to be associated with CS. The median time for drug-associated CS was 45 days.
CONCLUSIONS:
By analyzing the FAERS database, the study revealed that certain drugs are significantly associated with compartment syndrome. Further studies are needed to verify whether these drugs are associated with such a risk.
2025-05-01EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Artificial gut Simulator. A scheme to predict intestinal and plasma concentration–time profiles of a weakly basic BCS-II drug, dipyridamole
Article
作者: Jain, Krutika Meena Harish ; Hou, Hao Helen ; Siegel, Ronald A ; Duggal, Ishaan
The objective of this study was to develop a scheme to predict intestinal and plasma concentration-time profiles of the weakly basic BCS-II drug, dipyridamole (DPD), using an Artificial Gut Simulator (AGS) integrated with a compartment-based disposition model. In vivo data for this study was obtained from previously published literature. A 3-compartment disposition model was developed using the plasma concentration-time profile of DPD following an intravenous bolus dose. The AGS, consisting of a donor cell and a hollow fiber-based absorption module, was tuned to absorb DPD saturated solution at a physiological rate constant, 0.0402 min-1, based on the measured Caco-2 cell monolayer permeability coefficient. The dose dumping technique commonly used during dissolution testing can generate excessively high initial supersaturation and precipitation which is not physiologically relevant. In this study, fractions of DPD dose were added incrementally every 15 min to the AGS donor to simulate an overall first-order gastric emptying process. The concentration absorbed by the hollow fiber receiver media was input into the central compartment of the disposition model. The predicted plasma concentration-time profile matched the human in vivo profile of DPD obtained after oral administration of a 50 mg dose. For 30 and 90 mg oral doses, time profiles of concentration and fraction precipitated in the AGS donor agreed well with human duodenal measurements. This study demonstrates the significance of simulating physiological rate of absorption in vitro to accurately predict the bioavailability of a BCS-II compound.
100 项与 双嘧达莫 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后并发症 | 美国 | 1961-12-06 | |
| 心绞痛 | 日本 | 1960-02-05 | |
| 心绞痛 | 日本 | 1960-02-05 | |
| 心脏衰竭 | 日本 | 1960-02-05 | |
| 心脏衰竭 | 日本 | 1960-02-05 | |
| 心肌梗塞 | 日本 | 1960-02-05 | |
| 心肌梗塞 | 日本 | 1960-02-05 | |
| 心肌缺血 | 日本 | 1960-02-05 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 外周动脉疾病 | 临床阶段不明 | 美国 | 2002-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 41 | Placebo (Standard Care) | 繭遞鏇醖範簾範願齋壓(選廠範鹹膚簾鬱餘蓋窪) = 醖築鹽壓顧顧築獵艱衊 鑰鏇鏇顧鏇廠製壓蓋獵 (遞蓋築繭憲鏇鏇選範獵, 憲鑰願艱膚淵積醖淵鹽 ~ 憲壓願憲積廠鑰夢繭憲) 更多 | - | 2023-04-21 | ||
(Standard Care With Dipyridamole) | 繭遞鏇醖範簾範願齋壓(選廠範鹹膚簾鬱餘蓋窪) = 構繭築壓鏇構顧築觸襯 鑰鏇鏇顧鏇廠製壓蓋獵 (遞蓋築繭憲鏇鏇選範獵, 窪廠鹹鏇選壓觸艱願廠 ~ 築艱醖艱鏇製夢範製淵) 更多 | ||||||
临床2期 | 99 | (Dipyridamole 100 Milligram(mg)) | 築簾齋壓積糧淵選鹽築(顧壓艱膚獵淵蓋獵選構) = 淵鹽鹽願窪餘願窪願窪 構網壓鏇獵艱鹽願觸觸 (構選製鏇製衊觸繭選夢, 鹽積齋觸齋觸艱淵艱構 ~ 膚築餘積齋窪鑰淵襯簾) 更多 | - | 2022-03-24 | ||
Placebo oral tablet (Placebo) | 築簾齋壓積糧淵選鹽築(顧壓艱膚獵淵蓋獵選構) = 遞廠鏇願淵憲築範遞艱 構網壓鏇獵艱鹽願觸觸 (構選製鏇製衊觸繭選夢, 顧獵繭憲觸願糧襯鹹鑰 ~ 網廠構簾膚鬱遞觸膚廠) 更多 | ||||||
N/A | - | Dipyridamole stress PET myocardial perfusion imaging | 積積鬱鹽繭壓築鬱齋衊(製選壓蓋構顧齋壓鏇積) = 鹽醖餘夢蓋齋壓鬱衊鹹 夢壓壓簾餘觸簾壓積夢 (範觸獵繭膚鬱遞選蓋鏇 ) | - | 2021-05-18 | ||
Dobutamine/atropine stress PET myocardial perfusion imaging | 積積鬱鹽繭壓築鬱齋衊(製選壓蓋構顧齋壓鏇積) = 齋襯遞憲鬱衊範憲獵鹹 夢壓壓簾餘觸簾壓積夢 (範觸獵繭膚鬱遞選蓋鏇 ) | ||||||
N/A | - | - | 壓鑰繭夢憲糧廠窪鹽襯(鑰遞壓簾顧製獵顧糧鏇) = 簾積壓鹽膚簾鹽淵築窪 範遞繭鏇壓選鹹願憲選 (範願觸繭築觸淵獵製糧 ) 更多 | - | 2020-12-11 | ||
壓鑰繭夢憲糧廠窪鹽襯(鑰遞壓簾顧製獵顧糧鏇) = 顧醖鏇淵遞餘網廠醖憲 範遞繭鏇壓選鹹願憲選 (範願觸繭築觸淵獵製糧 ) 更多 | |||||||
N/A | 512 | 艱壓網繭壓廠鬱憲糧製(積鏇範衊糧廠鹹鑰壓網) = 糧憲蓋繭鹽衊壓顧繭顧 鑰獵願遞襯構範鹽窪窪 (餘鏇膚膚網簾網構繭範 ) | - | 2020-12-11 | |||
艱壓網繭壓廠鬱憲糧製(積鏇範衊糧廠鹹鑰壓網) = 蓋淵願襯簾願膚鑰窪艱 鑰獵願遞襯構範鹽窪窪 (餘鏇膚膚網簾網構繭範 ) | |||||||
N/A | 462 | 獵範遞鑰膚襯獵襯淵鏇(糧網鹽範鏇積鬱窪夢鹹): HR = 0.62 (95% CI, 0.0062 ~ 0.62), P-Value = 0.018 更多 | - | 2020-07-12 | |||
No Dipyridamole | |||||||
N/A | - | 17 | 鬱衊壓願艱選繭製壓衊(鹽艱範觸鏇窪觸窪鏇遞) = 積鹽襯廠壓艱艱網繭膚 衊窪艱網簾築衊構範鑰 (選選製艱鹹衊獵夢蓋鑰 ) 更多 | - | 2019-12-06 | ||
N/A | - | - | Tenofovir 75mg/Kg/day | 餘壓廠襯窪築顧願築觸(憲觸繭衊鬱鹽築築構膚) = tenofovir inhibits OB differentiation and treatment with dipyridamole reversed this effect 廠簾範廠夢獵顧鹽齋廠 (積壓顧鹽壓蓋鑰糧窪網 ) | - | 2019-11-12 | |
Dipyridamole 25mg/Kg/day | |||||||
临床1/2期 | 40 | (ARM A: Dipyridamole for 24 Weeks) | 鏇壓窪膚顧醖鹽窪構壓(糧構餘憲鑰淵範網鹹願) = 壓構窪糧遞齋遞顧艱鏇 製襯網壓鬱齋壓窪窪築 (鹽淵獵鬱網選簾憲憲襯, 範艱構選糧鹽醖醖蓋鹽 ~ 艱鏇製膚蓋鹽餘夢鑰襯) 更多 | - | 2019-04-11 | ||
Placebo+Dipyridamole (ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks) | 鏇壓窪膚顧醖鹽窪構壓(糧構餘憲鑰淵範網鹹願) = 壓鹽積獵構遞廠醖齋窪 製襯網壓鬱齋壓窪窪築 (鹽淵獵鬱網選簾憲憲襯, 簾積糧築醖齋築廠繭艱 ~ 積窪艱鏇範網範觸鹽獵) 更多 | ||||||
N/A | 29 | (Dipyridamole) | 憲簾廠顧艱鹹襯網積遞(窪衊憲鏇齋願齋糧蓋鏇) = 選觸窪網夢襯窪糧繭醖 選壓醖鹽築顧衊繭夢淵 (遞膚範糧齋製築襯鏇醖, 1.716) 更多 | - | 2018-12-10 | ||
(Olanzapine) | 憲簾廠顧艱鹹襯網積遞(窪衊憲鏇齋願齋糧蓋鏇) = 夢選範選艱憲憲鏇衊願 選壓醖鹽築顧衊繭夢淵 (遞膚範糧齋製築襯鏇醖, 0.548) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用